Drugs / Fosapirtan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07617246 Comparator | Nov 2025 → Jan 2027 expected | esophageal cancer, lung cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosapirtan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617246 ↗ |
| Known as | fosapirtan dimeglumine | “Fosapirtan dimeglumine for injection: 150mg, intravenous drip for 20-30 minutes, administered once before each cycle of chemotherapy.” NCT07617246 ↗ |
| Route | Intravenous | “intravenous drip for 20-30 minutes” NCT07617246 ↗ |